0.9199
0.49%
-0.0045
Seres Therapeutics Inc Borsa (MCRB) Ultime notizie
Seres Therapeutics executive sells shares worth $792 By Investing.com - Investing.com
Investing.com
Seres Therapeutics executive sells shares worth $837 By Investing.com - Investing.com
Investing.com
Seres Therapeutics executive sells shares worth $837 By Investing.com - Investing.com Canada
Investing.com Canada
Seres Therapeutics executive sells shares worth $882 - Investing.com ZA - Investing.com South Africa
Investing.com South Africa
Seres Therapeutics executive sells shares worth $882 By Investing.com - Investing.com
Investing.com
Seres Therapeutics CEO sells $2,288 in stock By Investing.com - Investing.com Canada
Investing.com Canada
Seres Therapeutics CEO sells $2,288 in stock By Investing.com - Investing.com
Investing.com
Seres Therapeutics executive sells shares worth $660 - Investing.com India
Investing.com India
Seres Therapeutics executive sells shares worth $660 - Investing.com ZA - Investing.com South Africa
Investing.com South Africa
Seres Therapeutics executive sells shares worth $660 By Investing.com - Investing.com
Investing.com
Seres Therapeutics (NASDAQ:MCRB) Shares Cross Above 50 Day Moving Average of $0.82 - MarketBeat
MarketBeat
Seres Therapeutics (NASDAQ:MCRB) Shares Cross Above 50 Day Moving Average of $0.82 - Defense World
Defense World
Earnings call: Seres Therapeutics reports on Q1 2024 with VOWST updates - Investing.com
Investing.com
Earnings call: Seres Therapeutics reports on Q1 2024 with VOWST updates - Investing.com India
Investing.com India
Seres Therapeutics (MCRB) Q3 Earnings and Revenues Beat Estimates - Yahoo New Zealand News
Yahoo New Zealand News
Seres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2024 Earnings Call Transcript - Insider Monkey
Insider Monkey
Chardan Capital Lowers Seres Therapeutics (NASDAQ:MCRB) Price Target to $6.00 - Defense World
Defense World
Seres Therapeutics (NASDAQ:MCRB) Price Target Cut to $4.00 by Analysts at Oppenheimer - MarketBeat
MarketBeat
Seres Therapeutics (MCRB) in Focus: Stock Up 5.5% in Session - Yahoo Movies Canada
Yahoo Movies Canada
Seres Therapeutics stock target cut amid sales dip - Investing.com Canada
Investing.com Canada
Seres Therapeutics Inc (MCRB) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights and Financial ... - GuruFocus.com
GuruFocus.com
Seres Therapeutics shares target cut by Oppenheimer amid sales dip - Investing.com Canada
Investing.com Canada
Seres Therapeutics stock target cut amid sales dip - Investing.com India
Investing.com India
Seres Therapeutics First Quarter 2024 Earnings: US$0.28 loss per share (vs US$0.56 loss in 1Q 2023) - Yahoo Finance
Yahoo Finance
Seres Therapeutics (NASDAQ:MCRB) Price Target Cut to $4.00 by Analysts at Oppenheimer - MarketBeat
MarketBeat
Seres Therapeutics at Risk of Nasdaq Delisting: A Race Against Time to Bolster Stock Value - TipRanks.com - TipRanks
TipRanks
Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates - citybiz
citybiz
Seres Therapeutics Reports Q1 2024 Earnings: Surpasses Revenue Estimates - GuruFocus.com
GuruFocus.com
Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates - 08.05.2024 - wallstreet:online
wallstreet:online
Seres Therapeutics: Q1 Earnings Snapshot - Milford Mirror
Milford Mirror
Seres Therapeutics (MCRB) Set to Announce Quarterly Earnings on Wednesday - MarketBeat
MarketBeat
Analysts Are Betting On Seres Therapeutics, Inc. (NASDAQ:MCRB) With A Big Upgrade This Week - Yahoo Movies Canada
Yahoo Movies Canada
Seres Therapeutics (MCRB) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Lifestyle Australia
Yahoo Lifestyle Australia
Seres Therapeutics (MCRB) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Lifestyle UK
Yahoo Lifestyle UK
Increases to Seres Therapeutics, Inc.'s (NASDAQ:MCRB) CEO Compensation Might Cool off for now - Yahoo Finance
Yahoo Finance
Institutional owners may take dramatic actions as Seres Therapeutics, Inc.'s (NASDAQ:MCRB) recent 25% drop adds to one-year losses - Simply Wall St
Simply Wall St
Chardan Capital Comments on Seres Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:MCRB) - MarketBeat
MarketBeat
Seres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2023 Earnings Call Transcript - Yahoo Finance
Yahoo Finance
Emerson Electric To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Wednesday
Benzinga
Earnings call: Seres Therapeutics reports promising VOWST launch - Investing.com
Investing.com
A New Cause for Concern: Seres Therapeutics Inc. Adds a New Supply Chain Risk - TipRanks.com - TipRanks
TipRanks
Pamela Stephenson to head commercial at Disc - BioCentury
BioCentury
Seres Therapeutics Announces Executive Leadership Transition and New CFO Compensation Details - TipRanks.com - TipRanks
TipRanks
Seres Therapeutics appoints new CFO as Arkowitz retires - Investing.com
Investing.com
MCRB Stock Quote Price and Forecast - CNN
CNN
Seres Therapeutics Announces 2024 Virtual Stockholders Meeting - TipRanks.com - TipRanks
TipRanks
Halozyme Therapeutics (HALO) Surges 5.6%: Is This an Indication of Further Gains?
Zacks Investment Research
Dow Tumbles Over 200 Points; US Trade Gap Narrows In November
Benzinga
Seres Therapeutics, Inc. (NASDAQ:MCRB) is a favorite amongst institutional investors who own 62% - Yahoo Finance
Yahoo Finance
Seres: Evaluating Vowst's Market Challenges (Rating Downgrade) (NASDAQ:MCRB) - Seeking Alpha
Seeking Alpha
Capitalizzazione:
|
Volume (24 ore):